Get started

Undervalued

ULTA looking to make new all time highs!ULTA (Ulta Beauty, Inc) is testing resistance around the $355 area that dates back to mid 2019. Fundamentally, * It's undervalued with a PEG of 0.77 * Its earnings per share is expected to grow over the coming year. Technically, * General up trend * Beta > 1 (following the general market trend) * Broke above the resistance of $315 that dates back to 2017 and retested it as support * It's approaching and testing resistance that dates back to 2019 and is looking to break through Final thoughts: * This is a good long term hold as the company is generally doing really well. * It's currently undervalued, meaning it's actually worth more than the current price. * Now would be a good time to get in if you're looking to hold this for the long term. * If you're looking for a discount, look for buying opportunities around the $340 area * If the price closes below $340 then look for buying opportunities around the $330 area. Alternatively, if you like to buy high and sell higher, you can look for the price to make a weekly close above $355.36.
NASDAQ:ULTALong
by HaseebKhan_90
DOT/USDT is massively undervaluedPolkadot is one of the most undervalued high cap coin at the moment. Currently, more than 450+ projects building on Polkadot. This could easily overtake Cardano's spot. Currently down 70% from ATH. Best time to accumulate much as we can. If DOT stays within the uptrend we could see a new ATH with 3x 5x growth from the entry at the end of this year. This prediction is more suitable for long term investors and anyone looking to accumulate more DOT. This is not financial advice. Please DYOR on fundamentals
Long
by CryptoCafeClub
1
Mask Network - Be Greedy Whilst Others Are Fearful Mask network is one of the newest coins to hit Coinbase. (showing KuCoin chart due to longer price history) Highly speculative play anticipating a reversal or short rally. Price has collapsed 96% which is very lucrative in my opinion. This coin has a rather high inflation rate but low total supply so with demand it should not be an issue. Something to watch for. My conservative target would be a test of the upper Bollinger Band around $21. Potential for massive returns in a relatively short timeframe. As I said, HIGHLY speculative but worth the risk for me. Not Financial Advice.
Long
by MitchMilli
2
easy money at these levelsThis is one of my favorite companies out there in this space, and it cannot be any more undervalued in my honest opinion. I have loaded up on this in yesterdays trading session, bringing my average cost down to $11.75. It is now roughly 15% of my portfoilo because i know that these price levels are a steal! Please do some DD in the company and you will see that it is worth your investment. I have a Price Target of at least $25 in the next 1-3 years if the company coninues to meet estimates going forward. Easy Money. Easier then APRE was if you were following my previous trades. (APRE ended up as 20%+ gainer but i had to hold for close to 4 months to see profit) NYSE:DM
NYSE:DMLong
by FinanceGuy204
1
Buy SCHNEIDER ELECTRIC for 1-3 years Bullish golden crossover of 50VWMA and 200SMA indicating bullish potential upside. Also, a 3-year old base breakout has already occurred and price is currently hovering just above breakout level (between 120-125) RSI also confirming base breakout. ADX marking a fresh 5 YEAR HIGH! Potential targets are 188.15 and then 219-226. Stop loss can be kept at 97.45 Thus Risk/Reward ratio is favourable at 2.43 and 3.89 (for both targets mentioned above respectively) NOTE: All the above analysis is based on weekly charts.
NSE:SCHNEIDERLong
by Samyak_Shah
Is $CHWY a $100 stock? *Before reading the information in this please understand the risks associated with both the stock market and investing as a whole. ALWAYS do your own research; invest with conviction, rather than emotion.* *Please understand I am in no way a professional and offering investment advice, all ideas shared are simply opinion.* *I work with a team of individuals that does research into potentially undervalued publicly traded companies. We use a mix of fundamental and trend analysis to formulate a trading plan for our securities.* My team and I have had our eye on Chewy ($CHWY) for some time, and in its current bullish trend we believe this pet-good provider has potential for both short and long term growth. Their most recent earnings report was a breath of fresh air, going against analyst expectation of reported loss. We believe that in its current operations, Chewy could potentially control their market simply based on the large variety of products they provide, as well as the level of convenience they bring their customers. Their lack of a brick-and-mortar setup allows convenient direct-to-consumer distribution, cutting out the middleman of a company such as Petco ($WOOF). The Coronavirus pandemic shifted consumer wants and needs, many consumers are searching for convenience in the delivery of their goods, and Chewy's operations have been set up to provide that convenience since its founding. Many companies have had to shift their operations to meet this demand, while Chewy has been able to grow in its operations in the past year; the company is in the midst of a 70% growth spurt from in a one year period. We believe this company is worth a share price of $100, and we believe its current valuation of $80 per share is low. My team secured an entry on Friday afternoon. ENTRY: $80 STOP LOSS: $70 TAKE PROFIT 1: $95 TAKE PROFIT 2: $100 TAKE PROFIT 3: $110 Check out my team over at @SimplyShowMeTheMoney Members of our team are followed there.
NYSE:CHWYLong
by tradebuckets
1
Ammo Inc. ($POWW) - Excellent Risk and Reward OpportunityAmmo Inc presents itself as an excellent opportunity in a market where a large number of stocks are significantly overvalued. Ammunition, as we know it, has been booming for a while since the pandemic and we're now in a shortage, which has allowed this business to position itself very nicely going forward. Roth has labeled a $9 price target on the business. Subsequent to the valuation, it was announced that Ammo Inc. has been included in the June 4th preliminary list of member additions to the Russell 2000® Index and the Russell Microcap® Index, which become effective upon the opening of the US stock markets on June 28, as part of the 2021 Russell indexes reconstitution. About (taken from their website): AMMO, Inc. is a high-quality, technology-driven ammunition U.S.-based company; from our patented STREAK (R), HyperClean, and military ammunition technologies, to the latest and best manufacturing technology in the industry. Our manufacturing facilities and processes meet or exceed all SAAMI and MilSpec specifications. Fundamentally, the company has established itself well and the underlying data can be found at FinViz Technically speaking, the Risk/Reward opportunity is excellent. We can see it has broken out to the upside and has retested the $7.00 mark (the upper trend line) to validate the breakout. Let's be mindful of where this stands after next Friday's close. If we close below $7.00 next Friday, I'll be unwinding my position. I have marked the Stops and Take Profit levels here accordingly. Good luck and be sure to maintain your stops accordingly.
NASDAQ:POWWLong
by MadebyTrade
2
$LCTX biotech company analysis *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share. My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20. ORIGINAL ENTRY: $2.23 AVERAGING UP AT: $2.70 TAKE PROFIT: $4.20 STOP PROFIT LOSS: $2.50 If you want to see more, please like and follow us @SimplyShowMeTheMoney
AMEX:LCTXLong
by SimplyShowMeTheMoney
Terra LunaLets talk about Terra and specifically Luna. Solid fundamentals, huge ecosystem, a fan favourite as a payments project. Not familiar, this will get your toes wet: How does Terra work? www.youtube.com Luna had an incredible run up in February like many altcoins did before going through a staggering 54 day accumulation period. During this time, most alts in the top 100 (all except CRO I believe, despite the launch of their Visa card) ran once or twice more, establishing new all time highs. Luna on the other hand, moved sideways, loading up like a spring, yet remaining highly sensitive to BTC downtrends. Many had their stop losses triggered during the violent BTC resistance rejection last night and are holding onto fiat scratching their heads. If you're cool calm and confident, take a look at Luna and Terra's ecosystem, and think about the current channel. I see this as undervalued.
by GrayAtreides
Co Diagnostics Inc Abnormal volume & undervalued 1 Year Price Target: $23.00 for a 180+/-% return About: Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
NASDAQ:CODXLong
by thedailyinvestor
Nuwellis Inc 🧙Revenue for the first quarter ended March 31, 2021, was $1.9 million, an increase of 18 percent compared to the prior-year period Increased Aquadex therapy utilization amongst strategic Critical Care accounts; highest levels seen in the past five quarters Enrolled first pediatric patient into the clinical registry in April 2021 Received strong endorsements for Category III CPT code application from two major medical societies Ended the quarter with $27.9 million in cash and no debt “Following our most recent $20.9 million capital raise with net proceeds of $18.9 million on March 19, 2021, Nuwellis is in a strong position to execute against our long-term strategic growth plan,” Revenue growth in the first quarter of 2021 was primarily driven by increased capital equipment sales and strong utilization within Critical Care. The Company also continued to see increasing utilization among established pediatric accounts during the quarter. Gross margin was 50.4% for the first quarter 2021, compared to 51.2% in the prior year period. The decline in gross margins was primarily due to strong sales of capital equipment. Selling, general and administrative (“SG&A”) expenses for the first quarter of 2021 were $5.2 million, an increase of 15% compared to the prior-year period. The increase in SG&A was primarily due to the timing of non-recurring administrative expenses and continued investment in sales and marketing activities. Research and development (“R&D”) expenses in the first quarter of 2021 were $0.9 million, an increase of 10% compared to the prior-year period. The increase in R&D expenses was driven primarily by clinical expenditures related to the pediatric registry. The net loss for the first quarter of 2021 was $5.2 million, compared to a net loss of $4.6 million in the prior-year period. Cash and cash equivalents were $27.9 million with no debt as of March 31, 2021. During the first quarter of 2021, the Company used $5.4 million of cash in operations. The Company also completed a $20.9 million capital raise with net proceeds of $18.9 million on March 19, 2021.
NASDAQ:NUWELong
by trading_as_bus
CREG Strong ConsolidationCREG, in the sector of energy, has in my opinion, consolidated at a price +/- 7$. The sector has a lot of potential and is extremely undervalued ($20M market cap when they have $100M in cash) and they recently completed and audited their 10-k application, which has amazing numbers. Here is a recap of their important numbers : Cash : $107,8M (2020) vs $16,2M (2019), which is an increase of 565%! Net income : $4,05M (2020) vs $-8,77M in losses (2019), an increase of 146%. Stock holder's equity : $92,15M (2020) vs $78,63M (2019), an increase of 17%. Book value : $29/share Cash value : $34/share This is not a recommandation nor am I a financial advisor. Do your own DDs, for me, it is a long term investment.
NASDAQ:CREGLong
by miheydudarevhec